409 related articles for article (PubMed ID: 33353234)
1. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.
van Bruggen JAC; Martens AWJ; Tonino SH; Kater AP
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33353234
[TBL] [Abstract][Full Text] [Related]
2. Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Weiss JM; Phillips TJ
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730677
[TBL] [Abstract][Full Text] [Related]
3. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
[TBL] [Abstract][Full Text] [Related]
4. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
Castagna L; Bono R; Tringali S; Sapienza G; Santoro A; Indovina A; Tarantino V; Di Noto L; Maggio A; Patti C
Front Med (Lausanne); 2022; 9():1072192. PubMed ID: 36561713
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
6. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
Pang Y; Ghosh N
Front Oncol; 2024; 14():1396395. PubMed ID: 38711850
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
Mol Ther; 2024 May; ():. PubMed ID: 38822527
[TBL] [Abstract][Full Text] [Related]
8. CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
Carulli G; Cannizzo E; Zucca A; Buda G; Orciuolo E; Marini A; Petrini M
Leuk Res; 2008 Feb; 32(2):263-7. PubMed ID: 17692374
[TBL] [Abstract][Full Text] [Related]
9. Targeting B-cell non Hodgkin lymphoma: New and old tricks.
Solimando AG; Ribatti D; Vacca A; Einsele H
Leuk Res; 2016 Mar; 42():93-104. PubMed ID: 26818572
[TBL] [Abstract][Full Text] [Related]
10. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
12. Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.
Tosolini M; Algans C; Pont F; Ycart B; Fournié JJ
Oncoimmunology; 2016 Jul; 5(7):e1188246. PubMed ID: 27622044
[TBL] [Abstract][Full Text] [Related]
13. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Kanwal B
Cureus; 2021 Jul; 13(7):e16307. PubMed ID: 34277304
[TBL] [Abstract][Full Text] [Related]
14. Reassessment of non-hodgkins's lymphoma with a "nodular" growth variant: a clinicopathologic study of follicular, mantle cell and marginal zone lymphomas prospectively diagnosed with multiparameter analyses.
Kadowaki I; Ichinohasama R; Sasaki O; Kimura J; Kameoka JI; Meguro K; Endo K; Tobinai K; Sasaki T; Sawai T; Ooya K
Leuk Lymphoma; 1998 Oct; 31(3-4):393-403. PubMed ID: 9869204
[TBL] [Abstract][Full Text] [Related]
15. Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment.
Watanabe T
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008305
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
[TBL] [Abstract][Full Text] [Related]
17. T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances.
Messéant O; Houot R; Manson G
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503084
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
19. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Akyurek N; Ren Y; Rassidakis GZ; Schlette EJ; Medeiros LJ
Cancer; 2006 Oct; 107(8):1844-51. PubMed ID: 16983704
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
